Global Ribonucleic Acid (RNA) Therapy Clinical Trials Market Set for Strong Expansion, Reaching $3.4 Billion With 4.7% CAGR by 2030
Uncover key drivers, emerging technologies, and competitive movements shaping the ribonucleic acid (rna) therapy clinical trials market from 2026–2035 with trusted insights from The Business Research Company
What market expansion outlook does the Ribonucleic Acid (RNA) Therapy Clinical Trials Market show for the 2026–2030 period?
The ribonucleic acid (rna) therapy clinical trials market size has experienced consistent expansion in recent years. It is projected to increase from $2.7 billion in 2025 to $2.83 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 4.8%. Historically, this growth can be linked to the scarcity of rna-based therapeutic options, the significant cost of early-stage clinical trials, obstacles in regulatory approval, limited public awareness of rna therapies, and a reliance on conventional therapeutic methods.
The ribonucleic acid (rna) therapy clinical trials market size is expected to demonstrate steady expansion over the next few years. It is projected to reach $3.4 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 4.7%. This anticipated growth is driven by improvements in rna delivery technologies, increased funding directed towards rare disease and anticancer research, expanding collaborations between biotech and pharmaceutical companies, the rising adoption of personalized medicine approaches, and the enlargement of global clinical trial networks. Major developments expected during this forecast period include an increasing number of rna therapy clinical trials across diverse therapeutic areas, a growing focus on rna therapeutics for rare diseases and cancer, the expansion of mrna vaccine and self-amplifying rna therapy trials, the uptake of crispr and rna editing-based therapy trials, and the integration of advanced delivery platforms along with oligonucleotide conjugates.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25896&type=smp
What Drivers Are Shaping The Development Of The Ribonucleic Acid (RNA) Therapy Clinical Trials Market?
The ribonucleic acid (RNA) therapy clinical trials market is projected to expand due to the escalating prevalence of infectious diseases. These diseases are health conditions resulting from pathogenic microorganisms like bacteria, viruses, fungi, or parasites that infiltrate the body, proliferate, and compromise well-being. A significant factor contributing to the surge in infectious diseases is the increase in worldwide travel, enabling the swift dissemination of pathogens across various areas and communities. Ribonucleic acid (RNA) therapy clinical trials are instrumental in combating infectious diseases through their capacity to foster the creation and assessment of specific treatments capable of rapidly adjusting to new pathogens. As an illustration, a report from the Minnesota Department of Health, a US-based state agency, indicated that in April 2025, the percentage of HIV cases among males aged 35 to 39 in 2024 rose from 10% in 2023 to 17%. Consequently, the rising impact of infectious diseases is fueling the expansion of the ribonucleic acid (RNA) therapy clinical trials market.
Which Segments Are Contributing To The Growth Of The Ribonucleic Acid (RNA) Therapy Clinical Trials Market?
The ribonucleic acid (rna) therapy clinical trials market covered in this report is segmented –
1) By Modality: Ribonucleic Acid (RNA) Interference, Antisense Therapy, Messenger Ribonucleic Acid (RNA), Oligonucleotide, Non-Antisense, Non-Ribonucleic Acid Interference (RNAi)
2) By Clinical Trials Phase: Phase I, Phase II, Phase III, Phase IV
3) By Therapeutic Areas: Rare Diseases, Anti-Infective, Anticancer, Neurological, Alimentary Or Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas
Subsegments:
1) By Ribonucleic Acid (RNA) Interference: Small Interfering RNA (siRNA) Therapy Trials, MicroRNA (miRNA)-Based Therapy Trials, Short Hairpin RNA (shRNA) Therapy Trials, Dicer Substrate RNA Therapy Trials
2) By Antisense Therapy: Gapmer Antisense Oligonucleotide Trials, Steric Blocking Antisense Trials, Splice-Switching Antisense Oligonucleotide Trials, Antisense Oligonucleotide-Conjugated Delivery Trials
3) By Messenger Ribonucleic Acid (RNA): mRNA-Based Vaccines Trials, Self-Amplifying mRNA (saRNA) Therapy Trials, Non-Replicating mRNA Therapy Trials, Circular mRNA Therapy Trials
4) By Oligonucleotide: Phosphorothioate Oligonucleotide Trials, Peptide Nucleic Acid (PNA) Trials, Locked Nucleic Acid (LNA) Trials, Morpholino Oligonucleotide Trials
5) By Non-Antisense: RNA Aptamer Therapy Trials, Guide RNA (gRNA)-Mediated CRISPR Trials, RNA Editing Therapy Trials, RNA Scaffolding Or Regulatory RNA Therapy Trials
6) By Non-Ribonucleic Acid Interference (RNAi): Ribozymes Therapy Trials, RNA Decoys Or Sponge RNA Trials, Long Non-Coding RNA (lncRNA) Therapy Trials, Small Activating RNA (saRNA) Therapy Trials
Which Competitive Trends Are Impacting The Structure Of The Ribonucleic Acid (RNA) Therapy Clinical Trials Market?
Leading companies within the ribonucleic acid (RNA) therapy clinical trials market are concentrating on developing innovative solutions, including RNA-based antisense oligonucleotide therapy clinical trials, to target specific genetic sequences, regulate gene expression, and provide highly precise treatments for genetic and rare diseases. An RNA-based antisense oligonucleotide therapy clinical trial involves a study that investigates the use of short synthetic RNA strands to bind specific messenger RNA targets, with the aim of modulating gene expression and treating genetic disorders. For instance, in December 2024, Sepul Bio, a France-based biotechnology company, initiated the LUNA Phase 2b clinical trial to evaluate ultevursen, an RNA-based antisense oligonucleotide therapy targeting mutations in exon 13 of the USH2A gene, which cause retinitis pigmentosa (RP) and Usher syndrome type 2a. This two-year, double-masked, randomized, sham-controlled study will enroll 81 adults and children aged eight and above across multiple global sites. The therapy is intended for individuals with RP or non-syndromic RP due to exon 13 mutations in USH2A, which can be confirmed by genetic testing. The LUNA trial follows promising results from earlier Phase 1/2 studies, where ultevursen demonstrated benefits in visual acuity, retinal sensitivity, and retinal structure.
Who Are The Core Companies Influencing Trends In The Ribonucleic Acid (RNA) Therapy Clinical Trials Market?
Major companies operating in the ribonucleic acid (rna) therapy clinical trials market are Pfizer Inc., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Moderna Inc., BioNTech SE, Biogen Inc., Daiichi Sankyo Company Limited, Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Ionis Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Arcturus Therapeutics Holdings Inc., Cartesian Therapeutics Inc., CureVac N.V., Orna Therapeutics Inc., Silence Therapeutics plc, ETHRIS GmbH, ProQR Therapeutics N.V., Lexeo Therapeutics Inc., Avidity Biosciences Inc., Aro Biotherapeutics Company, Wave Life Sciences Ltd.
Access The Complete Report For Deeper Market Insights:
Which Regions Are Projected To Dominate The Ribonucleic Acid (RNA) Therapy Clinical Trials Market In The Coming Years?
North America was the largest region in the ribonucleic acid (RNA) therapy clinical trials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ribonucleic acid (rna) therapy clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Ribonucleic Acid (RNA) Therapy Clinical Trials Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=25896&type=smp
Browse Through More Reports Similar to the Global Ribonucleic Acid (RNA) Therapy Clinical Trials Market 2026, By The Business Research Company
Ribose Nucleic Acid Rna Based Therapeutics Market Report 2026
Nucleic Acid Based Gene Therapy Market Report 2026
Ribonucleic Acid Rna Sequencing Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
